With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
It is the first autotaxin inhibitor to be investigated in cancer patients
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
The validations confirm the completion of the applications and commence the scientific review process
The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Acquisition of exclusive commercialization rights for European markets
Connecting new production and consumption areas of chilled food by low-carbon transportation services
Subscribe To Our Newsletter & Stay Updated
